0000000000907860
AUTHOR
G Marengo
Herceptin Resistance and Malignant Potential of Cancer Cells.
Proteomic analysis of Herceptin-resistance breast cancer cells
Herceptin-resistance in breast cancer cells: a proteomic study.
HER-2 is a cell membrane protein that belongs to the ErbB family of receptor tyrosine kinases (HER-1, HER-2, HER-3, HER-4). The over-expression of HER-2, which results in the 25-30% of breast cancer patients, is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness and makes HER-2 an excellent therapeutic target. In the last years new therapeutic strategies have been improved in order to better deal tumor diseases an to minimize collateral effects due to classic chemotherapy in patients. In this way, a new approach was the somministration of humanized antibodies directed against tumor-associated molecular targets. Among these ones Herceptin, an anti-neo…
Multiple effects induced by herceptin® on 8701-BC breast cancer cells
Herceptin, an anti-neoplastic humanized monoclonal antibody (Herceptin®, Roche, CH), has been shown to be active against breast cancer cells over-expressing HER-2 receptor. HER-2 is a cell membrane protein that belongs to the epidermal growth factor receptors family and that results over-expressed in the 25-30% of breast cancer patients. The over-expression of HER-2 is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness. On these bases, we aimed to analyze the effects caused by Herceptin treatment on 8701-BC breast cancer cells (Minafra et al., 1989). Firstly we evaluated the effects of Herceptin on the growth rate of 8701-BC cells. To this purpose, p…